Psyence Biomedical Ltd. (NASDAQ:PBM – Get Free Report) rose 7.9% on Thursday . The stock traded as high as $1.82 and last traded at $1.77. Approximately 181,792 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 460,805 shares. The stock had previously closed at $1.64.
Psyence Biomedical Price Performance
The company has a 50-day moving average price of $2.84 and a two-hundred day moving average price of $14.87.
Psyence Biomedical Company Profile
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
Further Reading
- Five stocks we like better than Psyence Biomedical
- Pros And Cons Of Monthly Dividend Stocks
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Dividend Capture Strategy: What You Need to Know
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Psyence Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psyence Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.